tradingkey.logo

Positive Late-Breaking Data For Incyte's First-In-Class Mutcalr-Targeted Therapy Inca033989 In Essential Thrombocythemia Presented At Eha2025

ReutersJun 15, 2025 7:17 AM

- Incyte Corp INCY.O:

  • POSITIVE LATE-BREAKING DATA FOR INCYTE’S FIRST-IN-CLASS MUTCALR-TARGETED THERAPY INCA033989 IN ESSENTIAL THROMBOCYTHEMIA PRESENTED AT EHA2025

  • INCYTE CORP - INCA033989 SHOWS POTENTIAL TO MODIFY DISEASE BY TARGETING MUTCALR CELLS

  • INCYTE CORP - 86% OF HIGH-RISK ET PATIENTS ACHIEVED HEMATOLOGIC RESPONSE WITH INCA033989

  • INCYTE CORP - 89% OF PATIENTS SHOWED REDUCTION IN MUTCALR VARIANT ALLELE FREQUENCY

  • INCYTE CORP - ONLY ONE PATIENT DISCONTINUED TREATMENT DUE TO TEAES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI